Literature DB >> 30140631

Long-term effect of triamcinolone acetonide in the treatment of upper lid retraction with thyroid associated ophthalmopathy.

Dong-Dong Xu1, Yu Chen2, Hai-Yan Xu1, Hui Li1, Zhu-Hua Zhang2, Yu-Hua Liu1.   

Abstract

AIM: To report the long-term outcomes of a large cohort of upper lid retraction patients treated with subconjunctival triamcinolone acetonide injections.
METHODS: This retrospective clinical study was conducted from 2009 to 2016. The documents of 97 patients (126 eyes) were reviewed. The patients were treated with subconjunctival triamcinolone acetonide injections monthly and evaluated pre- and post-treatment by taking measurements of the upper margin reflex distance (MRD1, the distance between the upper-lid margin and the pupil center), lid aperture, lagophthalmos and proptosis. The patients were divided into the cured group, the improved group and the ineffective group based on the final treatment effectiveness. The improved group and the ineffective group were combined into non-cured group.
RESULTS: The follow-up time was 23.45±14.86mo. Of the patients, 63 (64.9%) were assigned to the cured group, 22 (22.7%) in the improved group, 12 (12.4%) in the ineffective group. Injection times for cured group was 4.66±1.74, and for non-cured group was 5.17±2.08 (P≤0.05). The MRD1 was significantly reduced between baseline and 1mo after the initiation of treatment in the cured and improved groups (P<0.001). The values did not change significantly after 4mo for the improved group, while they continued to decrease in the cured group. In the ineffective group, the MRD1 did not significantly change after treatment. A statistically significant difference was observed between the baseline and post-treatment values of the mean muscle thickness (2.95±0.99 mm vs 2.04±0.63 mm, P<0.05) and surface area (27.27±10.5 mm2vs 18.3±7.04 mm2, P<0.05) of the levator superioris with magnetic resonance imaging examination. Twelve patients (12.4%) relapsed after treatment and required additional subconjunctival injections. The main side effects included menstrual cycle disturbances (32%) and elevations of intra-ocular pressure (18.6%).
CONCLUSION: A repeated subconjunctival injection of triamcinolone is an effective and relatively safe treatment for upper lid retraction due to thyroid-associated ophthalmopathy. This is related to the anti-inflammation effect of the medicine and the levator thickness can become thinner. Patients must be monitored regularly for recurrences and side effects.

Entities:  

Keywords:  eyelid retraction; magnetic resonance imaging; thyroid associated ophthalmopathy; triamcinolone acetonide

Year:  2018        PMID: 30140631      PMCID: PMC6090132          DOI: 10.18240/ijo.2018.08.07

Source DB:  PubMed          Journal:  Int J Ophthalmol        ISSN: 2222-3959            Impact factor:   1.779


  25 in total

1.  Ocular changes in Graves' disease. A long-term follow-up study.

Authors:  I B HALES; F F RUNDLE
Journal:  Q J Med       Date:  1960-01

Review 2.  Graves' orbitopathy: current imaging procedures.

Authors:  Eberhard Kirsch; Beat Hammer; Georg von Arx
Journal:  Swiss Med Wkly       Date:  2009-10-31       Impact factor: 2.193

3.  Disturbance of the menstrual pattern after local injection with triamcinolone acetonide.

Authors:  J M Mens; A Nico de Wolf; B J Berkhout; H J Stam
Journal:  Ann Rheum Dis       Date:  1998-11       Impact factor: 19.103

4.  Assessing Graves' ophthalmopathy-specific quality of life in Korean patients.

Authors:  Y J Choi; H T Lim; S J Lee; S Y Lee; J S Yoon
Journal:  Eye (Lond)       Date:  2012-01-13       Impact factor: 3.775

5.  Recurrent Thyroid Eye Disease.

Authors:  Payal Patel; Joyce Khandji; Michael Kazim
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2015 Nov-Dec       Impact factor: 1.746

6.  Fornix triamcinolone injection for thyroid orbitopathy.

Authors:  Shirin Hamed-Azzam; Abed Mukari; Ilan Feldman; Walid Saliba; Haneen Jabaly-Habib; Daniel Briscoe
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-02-12       Impact factor: 3.117

7.  Comparative study of Botox injection treatment for upper eyelid retraction with 6-month follow-up in patients with thyroid eye disease in the congestive or fibrotic stage.

Authors:  P G Costa; F P Saraiva; I C Pereira; M L R Monteiro; S Matayoshi
Journal:  Eye (Lond)       Date:  2008-06-06       Impact factor: 3.775

8.  Subconjunctival injection of triamcinolone in the treatment of lid retraction of patients with thyroid eye disease: a case series.

Authors:  E Chee; S-P Chee
Journal:  Eye (Lond)       Date:  2007-10-05       Impact factor: 3.775

9.  Modified Full Thickness Graded Blepharotomy for Upper Eyelid Retraction Associated With Thyroid Eye Disease in East Asians.

Authors:  Joonsik Lee; Hwa Lee; Minsoo Park; Sehyun Baek
Journal:  Ann Plast Surg       Date:  2016-12       Impact factor: 1.539

10.  Diagnosis and stage of Graves' ophthalmopathy: Efficacy of quantitative measurements of the lacrimal gland based on 3-T magnetic resonance imaging.

Authors:  Hao Hu; Xiao-Quan Xu; Fei-Yun Wu; Huan-Huan Chen; Guo-Yi Su; Jie Shen; Xun-Ning Hong; Hai-Bin Shi
Journal:  Exp Ther Med       Date:  2016-05-25       Impact factor: 2.447

View more
  3 in total

1.  Clinical features and clinical course of thyroid-associated ophthalmopathy: a case series of 3620 Chinese cases.

Authors:  Baixue Du; Yujiao Wang; Mei Yang; Weimin He
Journal:  Eye (Lond)       Date:  2020-11-02       Impact factor: 4.456

2.  Observations on the Efficacy of Two Methods for the Treatment of Upper Eyelid Retraction in Thyroid-Associated Ophthalmopathy.

Authors:  Dongping Li; Fengyuan Sun
Journal:  Biomed Res Int       Date:  2021-03-18       Impact factor: 3.411

3.  Triamcinolone acetonide injection in the treatment of upper eyelid retraction in Graves' ophthalmopathy evaluated by 3.0 Tesla magnetic resonance imaging.

Authors:  Miao Duan; Dong-Dong Xu; Hai-Long Zhou; Hong-Ying Fang; Wei Meng; Yi-Ning Wang; Zheng-Yu Jin; Yu Chen; Zhu-Hua Zhang
Journal:  Indian J Ophthalmol       Date:  2022-05       Impact factor: 2.969

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.